NK cell levels predict disease activity in patients with Multiple Sclerosis on Ocrelizumab/Rituximab therapy

被引：0
|
作者：
Dal Bello, Simone [1 ]
Lorenzut, Simone [2 ]
Saccomano, Emma [3 ]
Tereshko, Yan [1 ]
Cargnelutti, Daniela [2 ]
Cutuli, Daniela [2 ]
Gigli, Gian Luigi [3 ]
Valente, Mariarosaria [1 ,3 ]
机构：
[1] Hosp Santa Maria Misericordia, Clin Neurol, Udine, Italy
[2] Hosp Santa Maria Misericordia, Neurol, Udine, Italy
[3] Univ Udine, Dipartiment Med, Dipartimento Area Med, Univ Fruil, Udine, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1483/2062
引用
收藏
页码：944 / 945
页数：2
相关论文
共 50 条
  • [31] Disease activity in women with multiple sclerosis treated with rituximab and natalizumab
    Razaz, N.
    Piehl, F.
    McKay, K. A.
    Fink, K.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 396 - 397
  • [32] Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
    Maria Cellerino
    Giacomo Boffa
    Caterina Lapucci
    Francesco Tazza
    Elvira Sbragia
    Elisabetta Mancuso
    Nicolò Bruschi
    Simona Minguzzi
    Federico Ivaldi
    Ilaria Poirè
    Alice Laroni
    Gianluigi Mancardi
    Elisabetta Capello
    Antonio Uccelli
    Giovanni Novi
    Matilde Inglese
    Neurotherapeutics, 2021, 18 : 2579 - 2588
  • [33] Real world efficacy and safety profile of Ocrelizumab therapy in patients with multiple sclerosis
    Tran, V.
    Miller, P. A.
    Jarrar, R.
    Olson, J.
    Miller, T.
    Miravalle, A.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 864 - 864
  • [34] Effectiveness and safety of ocrelizumab in patients with multiple sclerosis
    Madrid-Paredes, A.
    Alvarez-Sanchez, R.
    Nieto-Gomez, P.
    Portillo-Haro, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 287 - 287
  • [35] Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
    Cellerino, Maria
    Boffa, Giacomo
    Lapucci, Caterina
    Tazza, Francesco
    Sbragia, Elvira
    Mancuso, Elisabetta
    Bruschi, Nicolo
    Minguzzi, Simona
    Ivaldi, Federico
    Poire, Ilaria
    Laroni, Alice
    Mancardi, Gianluigi
    Capello, Elisabetta
    Uccelli, Antonio
    Novi, Giovanni
    Inglese, Matilde
    NEUROTHERAPEUTICS, 2021, 18 (04) : 2579 - 2588
  • [36] Predictors of ocrelizumab effectiveness in patients with multiple sclerosis
    Cellerino, Maria
    Boffa, Giacomo
    Lapucci, Caterina
    Tazza, Francesco
    Sbragia, Elvira
    Mancuso, Elisabetta
    Bruschi, Nicolo
    Minguzzi, Simona
    Ivaldi, Federico
    Poire, Ilaria
    Laroni, Alice
    Mancardi, Gian Luigi
    Capello, Elisabetta
    Uccelli, Antonio
    Novi, Giovanni
    Inglese, Matilde
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [37] Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis
    Capasso, Nicola
    Nozzolillo, Agostino
    Scalia, Giulia
    Lanzillo, Roberta
    Carotenuto, Antonio
    De Angelis, Marcello
    Petruzzo, Martina
    Sacca, Francesco
    Russo, Cinzia Valeria
    Morra, Vincenzo Brescia
    Moccia, Marcello
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 49
  • [38] Cytokine levels and disease activity in Multiple Sclerosis
    Zeitoun, I
    Miron, S
    Copel, B
    Adunsky, A
    Achiron, A
    NEUROSCIENCE LETTERS, 1998, : S46 - S46
  • [39] A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis
    Evertsson, Bjorn
    Hoyt, Tammy
    Christensen, Angel
    AL Nimer, Faiez
    Foley, John
    Piehl, Fredrik
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2020, 6 (04)
  • [40] role of cd19+levels in efecctiveness in multiple sclerosis patients in treatment with ocrelizumab
    Meca, Virginia
    Dominguez Gallego, Marta
    Del Rio Munoz, Beatriz
    Aguirre, Clara
    Villar Guimerans, Luisa Maria
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1061 - 1061
12345